Hogan Lovells Supports EyePoint Pharmaceuticals in $150 Million Follow-On Public Offering

"Hogan Lovells has advised EyePoint Pharmaceuticals on its US$150 million follow-on public offering of equity securities, which includes 11 million shares of common stock priced at US$12 each and pre-funded warrants for an additional 1.5 million shares. This offering aims to support EyePoint's mission to develop innovative treatments for serious retinal diseases. The law firm has previously assisted EyePoint with other significant public offerings."

Hogan Lovells participated in the transaction by advising EyePoint Pharmaceuticals, Inc. on its US$150 million follow-on public offering of equity securities. The transaction involved EyePoint pricing an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of US$12 per share, along with pre-funded warrants to purchase an aggregate of 1,500,000 shares of its common stock at a price of US$11.999 per warrant. The total gross proceeds from this offering were approximately US$150 million, before deducting underwriting discounts and commissions and other offering expenses. The Hogan Lovells deal team included partner Stephen Nicolai (Philadelphia), associates Kayvon Paul and Athira Sivan (both Philadelphia), and law clerk Diane Shin (New York).

Hogan Lovells Supports EyePoint Pharmaceuticals in $150 Million Follow-On Public Offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads